Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Peptides
Esperance Pharmaceuticals, Inc

Organization & Developments: Esperance Pharmaceuticals

Parents

* Antibody drug conjugates (ADCs)
* Targeted Membrane disrupting peptides (MDPs)
Cationic lytic peptide (CLYPTM) technology platform
Developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells.
Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.
The Company was founded on patented technology discovered by scientists at the Pennington Biomedical Research Center, the Louisiana State (LSU) Ag Center and LSU main campus.